ANRS, Emerging Infectious Diseases

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Early Lung Cancer Diagnosis in HIV Infected Population With an Important Smoking History With Low Dose CT: a Pilot Study

Not Applicable

Completed

Conditions: Hiv Infection
Lung Cancer

Interventions: Radiation: Low dose computed tomography (CT)

First Posted Date: 2010-09-23

Last Posted Date: 2015-07-20

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 450

Registration Number: NCT01207986

Locations: 🇫🇷
Makinson, Montpellier, France

A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B

Phase 3

Conditions: Chronic Hepatitis B
AgHbs Negativation

Interventions: Drug: Pegylated interferon-alpha-2a
Drug: Nucleotidic or Nucleosidic Treatment

First Posted Date: 2010-07-29

Last Posted Date: 2013-03-29

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 185

Registration Number: NCT01172392

Locations: 🇫🇷
Hôpital Saint Joseph, Service d'hépatogastroentérologie, Marseille, France

Cohort of HIV Associated Lymphomas

Completed

Conditions: HIV Infection

First Posted Date: 2010-07-16

Last Posted Date: 2017-11-06

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 205

Registration Number: NCT01164436

Locations: 🇫🇷
BESSON, Paris, France

Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: AZT-3TC-LPV/r twice a day
Drug: ABC-3TC-EFV once a day

First Posted Date: 2010-05-20

Last Posted Date: 2016-07-12

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 161

Registration Number: NCT01127204

Locations: 🇧🇫
Service de pédiatrie - CHU Yalgado Ouedraogo, Ouagadougou, Burkina Faso
🇨🇮
CEPREF, Abidjan, Côte D'Ivoire
🇨🇮
FSU abobo-Avocatier, Abidjan, Côte D'Ivoire

and more 1 locations

Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)
Drug: darunavir/ritonavir QD + raltegravir BID

First Posted Date: 2010-02-10

Last Posted Date: 2013-11-06

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 800

Registration Number: NCT01066962

Locations: 🇮🇹
Torvergata University, Rome, Italy
🇪🇸
Hospital Clinic, Barcelona, Spain
🇮🇹
University of Brescia, Brescia, Italy

and more 74 locations

Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)

Phase 3

Completed

Conditions: HIV-1 Infections

Interventions: Drug: darunavir; ritonavir; emtricitabine/tenofovir
Drug: raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine

First Posted Date: 2009-12-16

Last Posted Date: 2014-02-05

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 90

Registration Number: NCT01033760

Locations: 🇫🇷
Hôpital Gustave Dron, Tourcoing, France

Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients

Phase 1

Completed

Conditions: HIV Infection
Liver Failure
Evidence of Liver Transplantation

Interventions: Drug: Raltegravir potassium

First Posted Date: 2009-12-01

Last Posted Date: 2013-07-18

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 14

Registration Number: NCT01022476

Locations: 🇫🇷
Service de Médecine Interne, Hôpital de Bicêtre, LE KREMLIN-BICETRE cedex, France

Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4

Phase 2

Conditions: Chronic Hepatitis C

Interventions: Drug: IFN alfa-2b XL 27 MUI + Ribavirin
Drug: IFN alfa-2b XL 36 MUI + Ribavirin
Drug: IFN peg alfa-2b 1.5 µg/kg + Ribavirin

First Posted Date: 2009-11-10

Last Posted Date: 2013-09-20

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 84

Registration Number: NCT01010646

Locations: 🇫🇷
Hôpital de la Croix Rousse, Lyon, France

Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)

Phase 3

Completed

Conditions: HIV
HIV Infections

Interventions: Drug: emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
Drug: abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
Drug: emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)

First Posted Date: 2009-06-25

Last Posted Date: 2017-02-27

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 454

Registration Number: NCT00928187

Locations: 🇧🇫
Day Hospital, CHU Sanou Souro, Bobo Dioulasso, Burkina Faso
🇨🇲
Day Hospital, Central Hospital, Yaounde, Cameroon
🇸🇳
Clinical Research and Training Center, Fann Hospital, Dakar, Senegal

Efficacy and Safety of Varenicline Among HIV-infected Patients

Phase 3

Completed

Conditions: HIV Infections
Tobacco Dependence

Interventions: Drug: Placebo
Drug: Varenicline

First Posted Date: 2009-06-11

Last Posted Date: 2014-07-29

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 248

Registration Number: NCT00918307

Locations: 🇫🇷
CHU de Bordeaux, Bordeaux, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy